1983~1988 Seoul National University College of Medicine, Seoul, M.D.
1993~1997 Seoul National University College of Medicine, Seoul, M.S.
1997~2001 Seoul National University College of Medicine, Seoul, Ph.D.
1998 ~ Present Staff, Department of Neurosurgery, Samsung Medical Center, Samsung Biomedical Research Institute, Seoul, Korea
2004 ~ 2009 Director, Division of Quality Assurance, Clinical Trial Center of Samsung Medical Center, Seoul, Korea
2009 ~ Present Director, Institute of Refractory Cancer Research, Samsung Medical Center, Seoul, Korea
2009 ~ Present Professor, Department of Neurosurgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Samsung Biomedical Research Institute, Seoul, Korea
2013 ~ 2016 Chairman, Graduate School, Department of Health Sciences & Technology, Sungkyunkwan University, Korea
2016 ~ Present Director, Tumor Evolution and Progression Working Group, Scientific Advisory Committee, Cancer Moonshot in Korea
Neuro-Oncology, Precision Medicine, Molecular Medicine, Regenerative Medicine, Neuroscience
Honors & Awards
2017. 09. Named to the Top 100 Major National R&D Outcome list
2016. 11. Pfizer Medical Research Award
2014. 08. Named on the 100 people who will brighten up Korea in 10 years (The Dong-A ILBO)
Realization of precision oncology using big data
The fundamental tenet of precision oncology involves genomic and molecular characterization of tumors to guide optimal therapeutic approach for individual patient. However, as most solid tumors harbor multiple genetic aberrations, predicting a successfully therapy based on genomic analysis alone remains challenging. An integrated approach consisting of genomic analysis of the patient tumor, in parallel with direct assessment of drug response on patient tumor derivatives is the next step towards precision oncology. Towards this goal, we have established a big-data driven comprehensive study of genomic and transcriptomic profiles of 462 patient tumor-derived cells (PDCs) across 14 different cancer lineages, together with response to 60 targeted agents. Through our robust and multi-layered analytical approach, we provide unprecedented insights into dynamic pharmacogenomic associations. Collectively, our systematic approach provides a significant conceptual advance towards precision oncology treatment.